# Contact TB-500 Legit: Corrections and Editorial Queries | TB-500

> Contact TB-500 Legit with corrections or editorial questions about our TB-500 research summaries. An editorial project — not a clinic, not a vendor, and not a source for medical advice or product.

Corrections, citation questions, and editorial feedback on the TB-500 digest.

## Editorial contact

Use this page to reach TB-500 Legit about the editorial content of the site — a correction to a citation, a study we should add to the TB-500 record, or a question about how we read a finding. We read every message about accuracy. If you can point to a primary source — a PubMed entry, a DOI, an FDA page — that helps us correct or extend the digest faster.

What this form is not: it is not a route to medical advice, a prescription, a clinician, or a product. We are an editorial project. We do not diagnose, treat, advise on personal use, or supply any substance, and we cannot answer questions about obtaining TB-500.

## What we can and cannot help with

We can help with editorial matters: corrections, sourcing questions, and pointers to peer-reviewed literature on TB-500 and thymosin beta-4. We cannot provide individual medical or legal guidance, recommend doses, interpret your situation, or direct you to a seller, pharmacy, clinic, or telehealth provider.

For questions about the regulatory standing, the [TB-500 legal status and FDA 503A category](/legal-status) page already sets out the current FDA position with its sources. For the science, the research and tissue-repair pages carry the cited findings. If something there is wrong or out of date, telling us is the most useful thing you can do.

---

The TB-500 literature drawn to spec on a single drawing sheet — the Ac-LKKTETQ fragment dimensioned out from its thymosin beta-4 parent, the empty human-trial cell left in the title block, and the FDA 503A standing stamped before anything else; no clinic drafted it and nothing here is dispensed or sold.